HUP9801829A3 - Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6 - Google Patents

Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6

Info

Publication number
HUP9801829A3
HUP9801829A3 HU9801829A HUP9801829A HUP9801829A3 HU P9801829 A3 HUP9801829 A3 HU P9801829A3 HU 9801829 A HU9801829 A HU 9801829A HU P9801829 A HUP9801829 A HU P9801829A HU P9801829 A3 HUP9801829 A3 HU P9801829A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
inhibiting effects
producing pharmaceutical
benzotiophene
derivatives
Prior art date
Application number
HU9801829A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP9801829A2 publication Critical patent/HUP9801829A2/hu
Publication of HUP9801829A3 publication Critical patent/HUP9801829A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HU9801829A 1995-02-06 1996-02-05 Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6 HUP9801829A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06

Publications (2)

Publication Number Publication Date
HUP9801829A2 HUP9801829A2 (hu) 1999-05-28
HUP9801829A3 true HUP9801829A3 (en) 1999-10-28

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801829A HUP9801829A3 (en) 1995-02-06 1996-02-05 Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6

Country Status (14)

Country Link
EP (1) EP0724879A2 (2)
JP (1) JPH10513470A (2)
KR (1) KR19980701933A (2)
CN (1) CN1173819A (2)
AU (1) AU708374B2 (2)
CA (1) CA2212232A1 (2)
CZ (1) CZ246597A3 (2)
FI (1) FI973235A0 (2)
HU (1) HUP9801829A3 (2)
IL (1) IL117036A0 (2)
NO (1) NO973609L (2)
WO (1) WO1996024356A1 (2)
YU (1) YU6996A (2)
ZA (1) ZA96897B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
KR20020009383A (ko) 1998-04-01 2002-02-01 우에노 도시오 축합 티오펜 유도체 및 이의 유도체를 유효 성분으로 하는약제
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
ES2207982T3 (es) * 1998-12-30 2004-06-01 Signal Pharmaceuticals, Inc. Compuestos y metodos para la modulacion de receptores estrogenicos.
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2005125043A (ru) * 2003-01-06 2006-01-27 Уайт (Us) Применение модуляторов альфа-рецепторов эстрогена для лечения рассеянного склероза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (2) * 1993-07-22 1997-04-21 Lilly Co Eli
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
EP0724879A2 (en) 1996-08-07
FI973235A7 (fi) 1997-08-05
KR19980701933A (ko) 1998-06-25
NO973609L (no) 1997-09-11
ZA96897B (en) 1997-08-05
WO1996024356A1 (en) 1996-08-15
NO973609D0 (no) 1997-08-05
FI973235L (fi) 1997-08-05
EP0724879A3 (2) 1996-09-11
MX9705940A (es) 1997-10-31
JPH10513470A (ja) 1998-12-22
IL117036A0 (en) 1996-06-18
CA2212232A1 (en) 1996-08-15
AU4916396A (en) 1996-08-27
AU708374B2 (en) 1999-08-05
HUP9801829A2 (hu) 1999-05-28
FI973235A0 (fi) 1997-08-05
CN1173819A (zh) 1998-02-18
CZ246597A3 (cs) 1998-06-17
YU6996A (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
HU9800291D0 (en) Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus
HUP9801532A3 (en) Use of benzimidazole derivatives for producing pharmaceutical compositions for inhibiting the growth of cancers
NZ304982A (en) Pyridinyloxy- or pyridinylamino-acetamide derivatives; pharmaceutical compositions
HUP0001267A3 (en) Use of rapamycin derivatives for the preparation of pharmaceutical compositions treating vasculopathies
IL117237A (en) Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
HUP9801877A3 (en) Medicaments containing tetrahydrofuryl-sulphonamide-derivative as inhibitors of aspartyl-proteases
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
HUP9801323A3 (en) Use of benzotiophene derivatives for producing pharmaceutical compositions a for inhibiting cell-cell adhesion
HUP9801995A3 (en) Substituted pyrimidine-thioalkyl and alkylether compounds and their use for producing pharmaceutical compositions
IL119778A (en) Neuropretective pharmaceutical compositions containing rapamycin derivatives
IL118294A0 (en) Preparation of 4-aryl-piperidine derivatives
IL115771A (en) Apolipoprotein-B synthesis inhibitors their preparation and pharmaceutical compositions containing them
IL118636A0 (en) Oral pharmaceutical compositions of s(+)-etodolac
IL123095A0 (en) Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers
IL123094A0 (en) Pharmaceutical compositions containing griseofulvin for inhibiting the growth of cancers
HUP9801993A3 (en) Ascomycin derivatives and their use for preparation of pharmaceutical compositions, process for their preparation and pharmaceutical compositions containing them
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
HUP9904638A3 (en) Use of benzopyrane derivatives for production of pharmaceutical compositions
HUP0000233A3 (en) Use of pyrazolinone derivatives for producing pharmaceutical compositions useful for treating disturbances of potency
HUP9801829A2 (hu) Benzotiofénszármazékok felhasználása IL-6 hatásainak inhibiálására alkalmas gyógyszerkészítmények előállítására
HUP9900748A3 (en) Use of pyrrolidine derivatives for producing pharmaceutical compositions suitable for treating alcoholism
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons
IL122191A0 (en) Pharmaceutical compositions containing substituted benzopyrans
HUP0001441A3 (en) Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives
HU9402237D0 (en) Use of benzene-sulfonyl-indol derivatives for producing pharmaceutical compositions